TG Therapeutics | TGTX - Gross Profit On Sales


TG Therapeutics reported $199.14M in Gross Profit on Sales for its fiscal quarter ending in June of 2026.





Gross Profit On Sales Change Date
AbbVie USD 14.39B 1.85B Jun/2026
Alaunos Therapeutics USD -1.13M 1.11M Sep/2024
Amgen USD 5.87B 1.02B Mar/2026
Ardelyx USD 89.66M 24.7M Mar/2026
Arrowhead Research USD 75.25M 1.52M Jun/2026
Bayer EUR 6.33B 1.84B Jun/2026
Biogen USD 2.12B 307M Jun/2026
Corcept Therapeutics USD 252.09M 90.07M Jun/2026
Curis USD 1.14M 8.86M Dec/2025
Gilead Sciences USD 6.8B 1.29B Jun/2026
J&J USD 18.55B 1.31B Jun/2026
Karyopharm Therapeutics USD 33.72M 1.13M Mar/2026
Novartis USD 11.24B 1.18B Jun/2026
Novavax USD 125.04M 76.09M Dec/2025
PTC Therapeutics USD 232.94M 84.56M Mar/2026
Puma Biotechnology USD 20.32M 24.85M Sep/2024
Regeneron Pharmaceuticals USD 3.71B 778.2M Jun/2026
Roche Holding CHF 22.69B 600M Jun/2026
TG Therapeutics USD 199.14M 27.73M Jun/2026
Verastem USD 15.62M 977K Mar/2026
Vertex Pharmaceuticals USD 2.84B 242.4M Jun/2026